PHILADELPHIA – September 03, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug ...

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results ...

Shire Receives Approvable Letter From FDA for Intuniv (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21, 2007 -- ...

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents First once-daily nonstimulant to be ...

The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission granted Marketing ...

Sept. 4 -- THURSDAY, Sept. 3 (HealthDay News) -- Intuniv (guanfacine) has been approved by the U.S. Food and Drug Administration to treat Attention-Deficit ...

Teva Pharmaceutical Industries Ltd is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker's units of illegally delaying the release of a generic ...

LONDON, July 28 (Reuters) - U.S. regulators have delayed approval of Shire's new extended-release hyperactivity drug Intuniv but the British company still expects it to be launched in the United ...

NEW ORLEANS British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating that administration of one of its drugs along with stimulants provided symptom ...

A fter your child is diagnosed with attention deficit hyperactivity disorder (ADHD), their pediatrician and other healthcare providers will recommend behavioral approaches that can help boost your ...

"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...

INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...